Article
Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia.
Expert opinion on biological therapy - 1 Sept 2013
Kanellopoulou Theoni, Alexopoulou Alexandra
Abstract excerpt
INTRODUCTION: Hereditary hemorrhagic telangiectasia (HHT) is a rare multisystem vascular disorder characterized by epistaxis, mucocutaneous telangiectases and visceral arteriovenous malformations predisposing to shunting and hemorrhage. Angiogenesis has been implicated in the pathogenesis of HHT and therefore angiogenesis inhibitors appear to be the most promising agents. A literature search was performed to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
